CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$2.37 USD
-0.02 (-0.84%)
Updated Aug 5, 2025 04:00 PM ET
Pre-Market: $2.39 +0.02 (0.84%) 8:08 AM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, CytomX Therapeutics, Inc. has a market cap of $192.68M, which represents its share price of $2.39 multiplied by its outstanding shares number of 80.62M. As a small-cap company, CTMX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CTMX 2.37 -0.02(-0.84%)
Will CTMX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
Other News for CTMX
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings)
CytomX Therapeutics (CTMX) Receives 'Outperform' Rating from Oppenheimer | CTMX Stock News
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX ...